Lapatinib (GW-572016) Ditosylate 化学構造
分子量: 925.46






  • Compare HER2 Inhibitors
  • 研究分野



製品説明 Lapatinib (GW-572016) Ditosylateは一種の有効なEGFRとErbB2阻害剤で、無細胞試験でIC50値が10.8と9.2 nMに分かれることです。
ターゲット EGFR ErbB2
IC50 10.8 nM 9.2 nM [1]
In vitro試験 Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]
In vivo試験 Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]
臨床試験 A Phase II study of Lapatinib in treating patients with recurrent prostate cancer has been completed.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

In vitro kinase assays The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.

細胞アッセイ: [1]

細胞株 HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2
濃度 Dissolved in DMSO, final concentrations ~100 μM
反応時間 72 hours
実験の流れ Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.

動物実験: [1]

動物モデル CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
製剤 Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)
投薬量 ~100 mg/kg
投与方法 Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Lapatinib (GW-572016) Ditosylate SDF
分子量 925.46


CAS No. 388082-77-7
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (108.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,di4-methylbenzenesulfonate

文献中の引用 (51)

Frequently Asked Questions

  • Question 1
    If I need to use S1028 for treating tumor-bearing mice with injection, how could I prepare the solution?

    Answer: S1028 Lapatinib Ditosylate can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as clear solution.



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related HER2 阻害剤

  • Erlotinib

    Erlotinibは一種のEGFR阻害剤で、このIC50値が2 nMです。Erlotinibは、EGFRに対する敏感性は人間c-Src或いはv-Abに対する敏感性より1000倍以上が高くなります。

  • R428 (BGB324)

    R428 (BGB324)は一種のAxl阻害剤で、IC50値が14 nMです。R428 (BGB324)は、Axlに作用する選択性はAblに作用する選択性より100倍以上が高くなって、MerとTyro3に作用する選択性より50倍-100倍が高くなって、InsR、EGFR、HER2とPDGFRβに作用する選択性より100倍余りが高くなります。

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397)は一種の経口有効な多ターゲットCSF-1R、KitとFlt3受容体チロシンキナーゼ阻害剤で、IC50値が20 nM、10 nMと160 nMにそれぞれ分かれることです。臨床3期。

  • PF-06463922

    PF-06463922は一種の有効な二重ALK/ ROS1阻害剤で、ROS1、ALK (WT)とALK (L1196M)に作用する時のKi値が0.02 nM以下、0.07 nM以下、0.7 nMにそれぞれ分かれることです。臨床1期。

  • AC480 (BMS-599626)

    AC480 (BMS-599626)は一種の選択性的で、有効なHER1とHER2阻害剤で、IC50値が20 nMと30 nMです。AC480 (BMS-599626)は、HER1とHER2に作用する効果はHER4に作用する効果より8倍左右が高くなって、VEGFR2、c-Kit、LckとMET等に作用する効果より100倍以上が高くなります。臨床1期。

  • CP-724714

    CP-724714は一種の有効で、選択性的なHER2/ErbB2阻害剤で、IC50値が10 nMです。無細胞試験で、CP-724714は、HER2/ErbB2に作用する選択性はEGFR、InsR、IRG-1R、PDGFR、VEGFR2、Abl、Src、c-Met等に作用する選択性より640倍以上が高くなります。臨床2期。

  • Neratinib (HKI-272)

    Neratinib (HKI-272)は一種の高度選択性的なHER2とEGFR阻害剤で、無細胞試験でIC50値が59 nMと92 nMに分かれることです。Neratinib (HKI-272)はKDRとSrcを微弱に抑制して、Akt、CDK1/2/4、IKK-2、MK-2、PDK1、c-Rafとc-Metに対して、著しい抑制作用がありません。臨床3期。

  • Sapitinib (AZD8931)

    Sapitinib (AZD8931)は一種の可逆的で、ATP競争性的なEGFR、ErbB2とErbB3阻害剤で、無細胞試験でIC50値が4 nM、3 nMと4 nMにそれぞれ分かれることです。AZD8931 (Sapitinib)はNSCLC細胞に作用する効果はGefitinib或いはLapatinibに作用する効果よりもっと強くて、ErbB家族に作用する選択性はMNK1とFltに作用する選択性より100倍が高くなります。臨床2期。

  • Mubritinib (TAK 165)

    Mubritinib (TAK-165)は一種の有効なHER2/ErbB2阻害剤で、BT-474細胞の中にIC50値が6 nMです。Mubritinib (TAK-165)はBT-474細胞系にEGFR、FGFR、PDGFR、JAK1、SrcとBlkを抑制する作用がありません。臨床1期。


Tags: Lapatinib (GW-572016) Ditosylateを買う | Lapatinib (GW-572016) Ditosylate供給者 | Lapatinib (GW-572016) Ditosylateを購入する | Lapatinib (GW-572016) Ditosylate費用 | Lapatinib (GW-572016) Ditosylate生産者 | オーダーLapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID